Palisade bio announces inducement grant under nasdaq listing rule 5635(c)(4)

Carlsbad, ca, jan. 03, 2025 (globe newswire) -- palisade bio, inc.  (nasdaq: pali) (“palisade”, “palisade bio”, or the “company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it had made an equity grant to a new employee under its 2021 inducement plan, as amended.
NDAQ Ratings Summary
NDAQ Quant Ranking